Starting or switching to bictegravir/emtricitabine/tenofovir alafenamide in clinical practice: pooled 12-month results from the global BICSTaR study

被引：0

作者：

Spinner, C. ^{[1
]}

Stoehr, A. ^{[2
]}

Wong, A. ^{[3
]}

de Wet, J. ^{[4
]}

Zeggagh, J. ^{[5
]}

Hocqueloux, L. ^{[6
]}

van Welzen, B. ^{[7
]}

Heinzkill, M. ^{[8
]}

Sahali, S. ^{[9
]}

Cornejo, A. Torres ^{[10
]}

Ramroth, H. ^{[11
]}

Haubrich, R. ^{[12
]}

Thorpe, D. ^{[13
]}

Kim, C. ^{[14
]}

机构：

[1] Tech Univ Munich, Univ Hosp Rechts Isar, Sch Med, Munich, Germany

[2] IFI Studien & Projekte GmbH, Zentrum Infektiol, Hamburg, Germany

[3] Univ Saskatchewan, Dept Med, Regina, SK, Canada

[4] Spectrum Hlth, Vancouver, BC, Canada

[5] Hop St Louis, AP HP, Serv Malad Infect, Paris, France

[6] CHR Orleans, Serv Malad Infect & Trop, Orleans, France

[7] Univ Med Ctr, Internal Med & Infect Dis, Utrecht, Netherlands

[8] Gilead Sci GmbH, HIV Med Affairs, Munich, Germany

[9] Gilead Sci, HIV Med Affairs, Paris, France

[10] Gilead Sci Netherlands BV, HIV Med Affairs, Amsterdam, Netherlands

[11] Gilead Sci Ltd, Pharmacovigilance & Epidemiol, London, England

[12] Gilead Sci Inc, Med Affairs Res, 353 Lakeside Dr, Foster City, CA 94404 USA

[13] Gilead Sci Europe Ltd, HIV Med Affairs, London, England

[14] Gilead Sci Canada Inc, HIV Med Affairs, Mississauga, ON, Canada

来源：

JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2020年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

P046

引用

页码：50 / 51

页数：2

共 50 条

[1] Starting or switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in clinical practice: pooled 12-month (12M) results from the global BICSTaR study
Spinner, Christoph
Stoehr, Albrecht
Wong, Alexander
de Wet, Joss
Zeggagh, Jeremy
Hocqueloux, Laurent
van Welzen, Berend
Heinzkill, Marion
Sahali, Sabrinel
Cornejo, Almudena Torres
Ramroth, Heribert
Haubrich, Richard
Thorpe, David
Kim, Connie
INFECTION, 2021, 49 (SUPPL 1) : S16 - S16
[2] Starting or switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in clinical practice: pooled 12-month (12M) results from the global BICSTaR study
Spinner, C.
Stoehr, A.
Wong, A.
De Wet, J.
Zeggagh, J.
Hocqueloux, L.
Welzen, B. V.
Heinzkill, M.
Sahali, S.
Cornejo, A.
Ramroth, H.
Haubrich, R.
Thorpe, D.
Lambert, J.
Kim, C.
HIV MEDICINE, 2021, 22 : 24 - 24
[3] Effectiveness, safety, and patient-reported outcomes of bictegravir/emtricitabine/tenofovir alafenamide in routine clinical care in Italy: 12-Month results from the BICSTaR cohort
Antinori, Andrea
Marchetti, Giulia
Esposito, Vincenzo
Rusconi, Stefano
Canetti, Diana
Quiros-Roldan, Eugenia
Candelaresi, Bianca
Saracino, Annalisa
Andreoni, Massimo
Marongiu, Andrea
Cassidy, Tali
Thorpe, David
Albini, Laura
Caldera, Roberto
Forcina, Gabriele
Di Perri, Giovanni
INTERNATIONAL JOURNAL OF STD & AIDS, 2025, 36 (04) : 309 - 318
[4] Effectiveness, safety, and patient-reported outcomes of bictegravir/emtricitabine/tenofovir alafenamide in routine clinical care in Italy: 12-Month results from the BICSTaR cohort ( Jan, 10.1177/09564624241308372, 2025)
Antinori, A.
Marchetti, G.
Esposito, V
INTERNATIONAL JOURNAL OF STD & AIDS, 2025, 36 (04) : 341 - 341
[5] Neuropsychiatric, clinical and laboratory changes in patients prospectively switching from elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide to bictegravir/emtricitabine/tenofovir alafenamide
Tiraboschi, J.
Prieto, P.
Saumoy, M.
Silva, A.
Imaz, A.
Scevola, S.
Fernandez-Olivares, G.
Navarro-Alcaraz, A.
Piatti, C.
Podzamczer, D.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 79 - 80
[6] Twelve-month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV from the Canadian cohort of the observational BICSTaR study
Wong, Alexander
Brunetta, Jason
De Wet, Joss
Logue, Ken
Loemba, Hugues
Saifi, Taban
Mumm, Dylana
Marongiu, Andrea
Harrison, Rebecca
Thorpe, David
Trottier, Benoit
MEDICINE, 2024, 103 (16) : E37785
[7] Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment: Efficacy and Tolerability in Clinical Practice
Canetti, Diana
Galli, Laura
Lolatto, Riccardo
Nozza, Silvia
Spagnuolo, Vincenzo
Muccini, Camilla
Trentacapilli, Benedetta
Bruzzesi, Elena
Ranzenigo, Martina
Chiurlo, Matteo
Castagna, Antonella
Gianotti, Nicola
DRUG DESIGN DEVELOPMENT AND THERAPY, 2023, 17 : 3697 - 3706
[8] Bictegravir/emtricitabine/tenofovir alafenamide in clinical practice for people with HIV: final 24-month effectiveness and safety outcomes in key populations in the observational BICSTaR cohort
Trottier, Benoit
Yang, Chia-Jui
Watanabe, Dai
Marchetti, Giulia
Elbirt, Daniel
De Barra, Eoghan
Gunduz, Alper
Lee, Sun Hee
Vogelmann, Roger
Robineau, Olivier
Choy, Chiaw Yee
Berrevoets, Marvin
Uriel, Alison
Thorpe, David
Heinzkill, Marion
Marongiu, Andrea
Ramroth, Johanna
D'Amato, Lisa
Mallolas, Josep
HIV RESEARCH & CLINICAL PRACTICE, 2025, 26 (01)
[9] Patient-reported outcomes after one year of routine clinical practice with bictegravir/emtricitabine/tenofovir alafenamide in PLWH: the BICSTaR cohort
Knechten, H.
Stephan, C.
Waizmann, M.
Brunetta, J.
Trottier, B.
Bonnet, F.
Duvivier, C.
van Welzen, B.
Mack, F.
Tossonian, H.
Thorpe, D.
Cornejo, A. Torres
Marongiu, A.
Curbelo, R.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 57 - 58
[10] Twelve-month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV: Real-world insights from BICSTaR cohorts
Esser, Stefan
Brunetta, Jason
Inciarte, Alexy
Levy, Itzchak
D'Arminio Monforte, Antonella
Lambert, John S.
van Welzen, Berend
Teruya, Katsuji
Boffito, Marta
Liu, Chun-Eng
Altuntas Aydin, Ozlem
Thorpe, David
Heinzkill, Marion
Marongiu, Andrea
Cassidy, Tali
Haubrich, Richard
D'Amato, Lisa
Robineau, Olivier
HIV MEDICINE, 2024, 25 (04) : 440 - 453

← 1 2 3 4 5 →